We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.4B
AUM Growth
-$764M
Cap. Flow
-$999M
Cap. Flow %
-41.57%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$27.4M
3
AZN icon
AstraZeneca
AZN
+$13.5M
4
GILD icon
Gilead Sciences
GILD
+$11.5M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 88.65%
2 Healthcare 9.88%
3 Technology 0.55%
4 Energy 0.39%
5 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPST icon
101
CALL
Tempest Therapeutics
TPST
$13M
– –
0
– –
VTRS icon
102
Viatris
VTRS
$19.1B
$3.37M 0.14%
+56,800
New +$3.24M
ASND icon
103
Ascendis Pharma A/S
ASND
$17.4B
$3.37M 0.14%
+194,023
New +$3.53M
BDSI
104
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.31M 0.14%
+3,152
New +$43.1K
RIBT
105
DELISTED
RiceBran Technologies
RIBT
$3.07M 0.13%
77,130
-2,790
-3% -$116K
XTLB
106
XTL Biopharmaceuticals
XTLB
$6.29M
$3.02M 0.13%
+65,573
New +$2.87M
AGTC
107
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3M 0.12%
+150,000
New +$3.35M
ABUS icon
108
Arbutus Biopharma
ABUS
$1.01B
$2.98M 0.12%
+170,821
New +$3.5M
ALKS icon
109
PUT
Alkermes
ALKS
$7.71B
$2.96M 0.12%
485
-771
-61% -$52.7K
NXTM
110
CALL
DELISTED
NxStage Medical Inc.
NXTM
$2.95M 0.12%
+1,703
New +$30.1K
IMUC
111
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$2.86M 0.12%
+147,226
New +$3.7M
ZGNX
112
CALL
DELISTED
Zogenix, Inc.
ZGNX
$2.77M 0.12%
+2,531
New +$28.6K
RPTP
113
CALL
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$2.76M 0.12%
+2,543
New +$26K
VRTX icon
114
CALL
Vertex Pharmaceuticals
VRTX
$132B
$2.76M 0.11%
234
-3,647
-94% -$437K
HALO icon
115
Halozyme
HALO
$12.3B
$2.74M 0.11%
+191,621
New +$2.76M
PRQR icon
116
ProQR Therapeutics
PRQR
$262M
$2.72M 0.11%
124,380
-128,703
-51% -$2.66M
NWBO
117
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$2.62M 0.11%
3,552
+158
+5% +$1.06K
RXDX
118
DELISTED
Ignyta, Inc.
RXDX
$2.58M 0.11%
259,032
-52,159
-17% -$390K
CELG
119
DELISTED
Celgene Corp
CELG
$2.56M 0.11%
+22,225
New +$2.66M
FWP
120
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.55M 0.11%
+12,866
New +$2.09M
OPK icon
121
Opko Health
OPK
$1.17B
$2.52M 0.1%
+177,551
New +$2.31M
TTOO
122
DELISTED
T2 Biosystems, Inc
TTOO
$2.51M 0.1%
32
+5
+19% +$464K
BGMS
123
Bio Green Med Solution Inc
BGMS
$5.94M
$2.48M 0.1%
+3
New +$2.12M
ABEO icon
124
Abeona Therapeutics
ABEO
$311M
$2.47M 0.1%
31,514
-8,110
-20% -$653K
ARWR icon
125
PUT
Arrowhead Research
ARWR
$11.7B
$2.43M 0.1%
+3,598
New +$25.5K
3 4
5
6 7

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, down 24% from $3.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $999M in Q1 2015, closing 85 positions and reducing 66 holdings. Its most notable exit was Pfizer, an estimated $42.1M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Sabby Management opened a new position in Tempest Therapeutics worth $4.69M.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value fell 24% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.